Chemical inhibitors of PISSLRE can exert their inhibitory effects through various mechanisms that impede the kinase activity of the protein. Staurosporine, for example, is a potent non-selective inhibitor of protein kinases, including members of the cyclin-dependent kinase (CDK) family to which PISSLRE belongs. By inhibiting CDKs, Staurosporine directly reduces the kinase activity of PISSLRE. Similarly, Roscovitine targets CDKs by selectively inhibiting their activity, which leads to a reduction in PISSLRE's ability to phosphorylate substrates. Olomoucine and Purvalanol A also bind to the ATP pocket of CDKs, preventing ATP from binding and thus inhibiting the phosphorylation activity of PISSLRE. Flavopiridol operates through competitive inhibition at the nucleotide-binding site, which blocks PISSLRE's access to ATP, necessary for its kinase function.
Alsterpaullone and Butyrolactone I both target CDKs, with Alsterpaullone competing with ATP for binding to the kinase domain, thus preventing PISSLRE from carrying out its kinase activity. Butyrolactone I, while being particularly selective for CDK2, also indirectly affects the activity of PISSLRE by inhibiting the phosphorylation events that PISSLRE would typically facilitate. Indirubin-3'-monoxime works by allosterically altering the kinase domain of CDKs, affecting the ability of PISSLRE to phosphorylate its substrates. Dinaciclib, AZD5438, and R547 are all strong inhibitors of multiple CDKs, which in turn decreases the kinase activity of PISSLRE. By inhibiting these kinases, these chemicals reduce the capacity of PISSLRE to add phosphate groups to its target proteins. Lastly, SNS-032, with its selectivity for CDKs such as CDK2, CDK7, and CDK9, impedes the kinase activity of PISSLRE, affecting the protein's role in cell cycle progression and signal transduction due to reduced substrate phosphorylation. Each of these chemicals disrupts the kinase activity of PISSLRE by targeting the ATP binding site, altering the kinase domain, or inhibiting the activity of closely related CDKs necessary for PISSLRE functionality.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including cyclin-dependent kinases (CDKs) which PISSLRE is a member of. By inhibiting CDKs, Staurosporine inhibits the kinase activity of PISSLRE directly. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine selectively inhibits CDKs such as CDK2, CDK7, and CDK9, which are closely related to PISSLRE's function. Inhibition of these kinases can reduce PISSLRE activity by limiting phosphorylation events that PISSLRE would otherwise catalyze. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective inhibitor of CDKs, and its mechanism includes the inhibition of kinase activity by competing with ATP binding sites. This would inhibit PISSLRE by preventing its ATP-dependent kinase activity. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits several CDKs, which leads to the inhibition of PISSLRE by hindering its kinase activity through competitive inhibition at the nucleotide-binding site. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is a selective inhibitor of CDKs. It binds to the ATP pocket of these kinases, which would inhibit PISSLRE by blocking its kinase activity. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
This compound is known to inhibit CDKs by allosterically altering the kinase domain which would prevent PISSLRE from phosphorylating its substrates. | ||||||
Butyrolactone I | 87414-49-1 | sc-201533 sc-201533A | 200 µg 1 mg | $120.00 $504.00 | 1 | |
Butyrolactone I is a selective inhibitor of CDKs, especially CDK2. Inhibition of CDK2 can reduce PISSLRE's activity by blocking downstream phosphorylation that PISSLRE would facilitate. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is a potent inhibitor of CDKs and inhibits PISSLRE kinase activity by competing with ATP for binding to the kinase domain. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib strongly inhibits multiple CDKs, thereby preventing PISSLRE from phosphorylating its target substrates due to reduced kinase activity. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 inhibits CDK1, CDK2, and CDK9, which are essential for cell cycle progression. By inhibiting these kinases, AZD5438 would decrease the phosphorylation capabilities of PISSLRE. | ||||||